Skip to main content
. 2018 Feb 27;16(2):e05182. doi: 10.2903/j.efsa.2018.5182

Figure 68.

Figure 68

Trends in ciprofloxacin, erythromycin and tetracycline resistance in Campylobacter jejuni from humans in reporting countries, 2013–2016

  • Statistically significant increasing trends over 3–4 years, as tested by logistic regression (p ≤ 0.05), were observed for ciprofloxacin in Austria, Estonia, France, Italy and Norway, for erythromycin in Lithuania, Norway and the United Kingdom and for tetracycline in Austria, Estonia, Italy, Lithuania and Slovenia. Statistically significant decreasing trends over 3–4 years were observed for ciprofloxacin in Malta and Spain, for erythromycin in Luxembourg and Malta. Only countries testing at least 10 isolates per year were included in the analysis.